Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 15.6 ug ml-1 | Compound was tested for its in vitro cytotoxicity in HCT-116 cell line after 72 hours | ChEMBL. | No reference |
IC50 (functional) | > 15.6 ug ml-1 | Compound was tested for its in vitro cytotoxicity in HCT-VP35 cell line after 72 hours | ChEMBL. | No reference |
LTS (functional) | = 6 | Anti-P388 Leukemia activity determined when compound 120 mg/kg was administered ip on day 26 on mice expressed as the Long -term survivors (LTS); mice alive/total No of mice tested=6 | ChEMBL. | No reference |
T/C (functional) | = 130 | Anti-P388 Leukemia activity after 70 mg/kg/injection ip administration on days 5 and 8 expressed as percent of median survival time of drug treated mice compared to saline treated controls. | ChEMBL. | No reference |
T/C (functional) | = 155 | Anti-P388 Leukemia activity after 140 mg/kg/injection ip administration on days 5 and 8 expressed as percent of median survival time of drug treated mice compared to saline treated controls. | ChEMBL. | No reference |
T/C (functional) | = 170 | Anti-P388 Leukemia activity after 280 mg/kg/injection ip administration on days 5 and 8 expressed as percent of median survival time of drug treated mice compared to saline treated controls. | ChEMBL. | No reference |
T/C (functional) | > 260 % | Anti-P388 Leukemia activity determined on mice expressed as the % Long -term survivors (LTS); mice alive/total | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.